Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer

被引：0
|
作者：
Zhang Yang
Shun-Qing Liang
Liang Zhao
Haitang Yang
Thomas M. Marti
Balazs Hegedüs
Yanyun Gao
Bin Zheng
Chun Chen
Wenxiang Wang
Patrick Dorn
Gregor J. Kocher
Ralph A. Schmid
Ren-Wang Peng
机构：
[1] Bern University Hospital,Division of General Thoracic Surgery and Department of BioMedical Research (DBMR), Inselspital
[2] University of Bern,Current address: Department of Thoracic Surgery, Shanghai Chest Hospital
[3] Current address: University of Massachusetts Medical School,Department of Thoracic Surgery
[4] Shanghai Jiao Tong University,Department of Thoracic surgery
[5] University Medicine Essen – Ruhrlandklinik,Thoracic Surgery Department 2, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine
[6] University Duisburg-Essen,undefined
[7] Fujian Medical University Union Hospital,undefined
[8] Central South University,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 41卷
关键词：
-mutant cancer; NOP56; mTOR; ROS; Synthetic lethal vulnerability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
    Yang, Zhang
    Liang, Shun-Qing
    Zhao, Liang
    Yang, Haitang
    Marti, Thomas M.
    Hegedus, Balazs
    Gao, Yanyun
    Zheng, Bin
    Chen, Chun
    Wang, Wenxiang
    Dorn, Patrick
    Kocher, Gregor J.
    Schmid, Ralph A.
    Peng, Ren-Wang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [2] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Xiufeng Pang
    Mingyao Liu
    癌症, 2016, 35 (11) : 571 - 573
  • [3] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Pang, Xiufeng
    Liu, Mingyao
    CHINESE JOURNAL OF CANCER, 2016, 35 : 92
  • [4] Targeting metabolic peculiarities: a potentially novel therapeutic approach for KRAS-mutant lung cancer?
    Abdel-Rahman, Omar
    JOURNAL OF THORACIC DISEASE, 2016, 8 (08) : E794 - E795
  • [5] Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer
    Feng, JuanJuan
    Jiang, Wenhao
    Liu, Yanan
    Huang, Wanfeng
    Hu, Kewen
    Li, Kun
    Chen, Jing
    Ma, Chengbin
    Sun, Zhenliang
    Pang, Xiufeng
    BIOCHEMICAL PHARMACOLOGY, 2020, 177
  • [6] Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
    Feng, Juanjuan
    Lian, Zhengke
    Xia, Xinting
    Lu, Yue
    Hu, Kewen
    Zhang, Yunpeng
    Liu, Yanan
    Hu, Longmiao
    Yuan, Kun
    Sun, Zhenliang
    Pang, Xiufeng
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (03) : 1145 - 1163
  • [7] Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
    Juanjuan Feng
    Zhengke Lian
    Xinting Xia
    Yue Lu
    Kewen Hu
    Yunpeng Zhang
    Yanan Liu
    Longmiao Hu
    Kun Yuan
    Zhenliang Sun
    Xiufeng Pang
    Acta Pharmaceutica Sinica B, 2023, (03) : 1145 - 1163
  • [8] Closing the door on KRAS-mutant lung cancer
    Cully, Megan
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (11) : 747 - 747
  • [9] Closing the door on KRAS-mutant lung cancer
    Megan Cully
    Nature Reviews Drug Discovery, 2016, 15 : 747 - 747
  • [10] Current therapy of KRAS-mutant lung cancer
    Ghimessy, Aron
    Radeczky, Peter
    Laszlo, Viktoria
    Hegedus, Balazs
    Renyi-Vamos, Ferenc
    Fillinger, Janos
    Klepetko, Walter
    Lang, Christian
    Dome, Balazs
    Megyesfalvi, Zsolt
    CANCER AND METASTASIS REVIEWS, 2020, 39 (04) : 1159 - 1177
12345